Investors Buy Shares of DexCom (DXCM) on Weakness After Insider Selling

Investors purchased shares of DexCom, Inc. (NASDAQ:DXCM) on weakness during trading on Thursday following insider selling activity. $90.05 million flowed into the stock on the tick-up and $29.87 million flowed out of the stock on the tick-down, for a money net flow of $60.18 million into the stock. Of all companies tracked, DexCom had the 16th highest net in-flow for the day. DexCom traded down ($0.61) for the day and closed at $146.85Specifically, insider Andrew K. Balo sold 10,917 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $142.79, for a total value of $1,558,838.43. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Donald Abbey sold 7,653 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $142.79, for a total value of $1,092,771.87. The disclosure for this sale can be found here. Insiders sold 102,181 shares of company stock worth $14,473,795 in the last ninety days. 1.80% of the stock is owned by corporate insiders.

Several research analysts have issued reports on the company. Cowen upped their price target on DexCom from $150.00 to $175.00 and gave the company an “outperform” rating in a report on Friday, February 22nd. Canaccord Genuity boosted their target price on shares of DexCom from $140.00 to $160.00 and gave the company a “buy” rating in a research note on Friday, February 22nd. Morgan Stanley boosted their target price on shares of DexCom from $135.00 to $160.00 and gave the company an “equal weight” rating in a research note on Monday, February 25th. Piper Jaffray Companies boosted their target price on shares of DexCom to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, January 9th. Finally, UBS Group boosted their target price on shares of DexCom from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, January 8th. Seven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $149.53.

The company has a debt-to-equity ratio of 1.52, a quick ratio of 7.32 and a current ratio of 7.64. The company has a market capitalization of $12.94 billion, a price-to-earnings ratio of 489.50 and a beta of 0.78.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 21st. The medical device company reported $0.54 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.38. DexCom had a negative net margin of 12.32% and a positive return on equity of 4.98%. The business had revenue of $338.00 million for the quarter, compared to the consensus estimate of $331.60 million. During the same period in the prior year, the business posted $0.10 earnings per share. DexCom’s revenue for the quarter was up 52.9% compared to the same quarter last year. Equities research analysts predict that DexCom, Inc. will post 0.46 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Laurel Wealth Advisors LLC acquired a new position in shares of DexCom in the fourth quarter worth $26,000. Harel Insurance Investments & Financial Services Ltd. bought a new stake in DexCom in the fourth quarter worth $33,000. First Hawaiian Bank boosted its holdings in DexCom by 75.6% in the fourth quarter. First Hawaiian Bank now owns 395 shares of the medical device company’s stock worth $47,000 after purchasing an additional 170 shares in the last quarter. Bremer Trust National Association bought a new stake in DexCom in the fourth quarter worth $49,000. Finally, LS Investment Advisors LLC bought a new stake in DexCom in the fourth quarter worth $67,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Investors Buy Shares of DexCom (DXCM) on Weakness After Insider Selling” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2019/03/15/investors-buy-shares-of-dexcom-dxcm-on-weakness-after-insider-selling.html.

DexCom Company Profile (NASDAQ:DXCM)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Read More: What is channel trading?

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.